KYNTRA BIO, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that KYNTRA BIO, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.44M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $29.62M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $46.80M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $140.73M | Feb 26, 2024 |
| FY2023 | Dec 31, 2021 | $235.31M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $176.32M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $256.58M | Mar 4, 2022 |
| FY2020 | Dec 31, 2018 | $212.96M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $131.00M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $183.19M | Feb 27, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.44M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $29.62M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $46.80M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $140.73M | Feb 26, 2024 |
| FY2023 | Dec 31, 2021 | $235.31M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $176.32M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $256.58M | Mar 4, 2022 |
| FY2020 | Dec 31, 2018 | $212.96M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $131.00M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $183.19M | Feb 27, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $183.45M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($47.58M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($284.23M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($293.65M) | Feb 26, 2024 |
| FY2023 | Dec 31, 2021 | ($290.02M) | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | ($189.29M) | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | ($76.97M) | Mar 4, 2022 |
| FY2020 | Dec 31, 2018 | ($86.42M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($120.88M) | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | ($58.07M) | Feb 27, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($45.90M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($150.42M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($322.72M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($301.03M) | Feb 26, 2024 |
| FY2023 | Dec 31, 2021 | ($288.53M) | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | ($191.88M) | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | ($89.31M) | Mar 4, 2022 |
| FY2020 | Dec 31, 2018 | ($86.69M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($117.28M) | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | ($50.04M) | Feb 27, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $23.52M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $95.69M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $266.47M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $296.79M | Feb 26, 2024 |
| FY2023 | Dec 31, 2021 | $387.04M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $252.92M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $209.27M | Mar 4, 2022 |
| FY2020 | Dec 31, 2018 | $235.84M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $196.52M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $187.21M | Feb 27, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.71M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $49.33M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $86.48M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $124.69M | Feb 26, 2024 |
| FY2023 | Dec 31, 2021 | $123.93M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $106.41M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $135.48M | Mar 4, 2022 |
| FY2020 | Dec 31, 2018 | $63.81M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $51.76M | Mar 2, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.77M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($138.00M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($315.02M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($145.93M) | Feb 26, 2024 |
| FY2023 | Dec 31, 2021 | ($82.23M) | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $81.60M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | ($78.71M) | Mar 4, 2022 |
| FY2020 | Dec 31, 2018 | ($76.14M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($66.51M) | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $7.11M | Feb 27, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $38.0K | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $266.0K | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $2.52M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $3.74M | Feb 26, 2024 |
| FY2023 | Dec 31, 2021 | $5.19M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $3.99M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $5.76M | Mar 4, 2022 |
| FY2020 | Dec 31, 2018 | $8.02M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $8.50M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $1.25M | Feb 27, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $119.59M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $214.53M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $423.53M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $610.09M | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $773.82M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $826.84M | Mar 4, 2022 |
| FY2020 | Dec 31, 2019 | $857.40M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $880.60M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $898.65M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $469.55M | Feb 27, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $115.12M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $398.16M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $585.73M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $611.57M | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $544.71M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $385.39M | Mar 4, 2022 |
| FY2020 | Dec 31, 2019 | $321.99M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $352.13M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $350.91M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $294.44M | Feb 27, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($30.04M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($225.60M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($204.17M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($21.45M) | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $209.15M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $422.18M | Mar 4, 2022 |
| FY2020 | Dec 31, 2019 | $516.14M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $509.20M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $528.47M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $155.84M | Feb 27, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.71B) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($1.89B) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($1.84B) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($1.56B) | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | ($1.26B) | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | ($974.01M) | Mar 4, 2022 |
| FY2020 | Dec 31, 2019 | ($784.72M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($715.83M) | Mar 2, 2020 |
| FY2019 | Dec 31, 2017 | ($630.66M) | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | ($509.78M) | Feb 27, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $47.87M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $50.48M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $81.55M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $155.70M | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $171.22M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $678.39M | Mar 4, 2022 |
| FY2020 | Dec 31, 2019 | $126.27M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $89.26M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $673.66M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $173.78M | Feb 27, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 29, 2025 | $75.00M | Mar 16, 2026 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 45 | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | (11) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | (3) | Feb 26, 2024 |
| FY2023 | Dec 31, 2021 | (3) | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Feb 27, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 45 | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | (11) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | (3) | Feb 26, 2024 |
| FY2023 | Dec 31, 2021 | (3) | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Feb 27, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4.05M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 4.04M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | 98.77M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | 94.17M | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | 92.88M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | 91.44M | Mar 4, 2022 |
| FY2020 | Dec 31, 2019 | 87.66M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | 85.43M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | 82.50M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | 63.67M | Feb 27, 2018 |